ASPEN PHARMACARE HOLDINGS LIMITED - Further announcement regarding acquisition of residual rights to Astrazeneca anaesthetics portfolio

Further announcement regarding acquisition of residual rights to Astrazeneca anaesthetics portfolio

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number: 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
(“Aspen Holdings”)



FURTHER ANNOUNCEMENT REGARDING ACQUISITION OF RESIDUAL RIGHTS TO ASTRAZENECA
ANAESTHETICS PORTFOLIO

Shareholders are referred to the announcement of Aspen Holdings’ provisional financial results for the year
ended 30 June 2017 released on 14 September 2017 wherein it was confirmed that:

    -   Aspen Global Incorporated (“AGI”) had signed an agreement with AstraZeneca AB and AstraZeneca
        UK (“AstraZeneca”) whereby AGI would acquire the residual rights to AstraZeneca’s global (excluding
        certain territories, most notably the USA) anaesthetic portfolio (“the Transaction”) for which it
        acquired the commercialisation rights via an agreement entered into in June 2016, as announced to
        shareholders on 9 June 2016; and

    -   subject to the fulfilment of customary closing conditions, the Transaction was anticipated to
        complete during the final quarter of the 2017 calendar year.

Aspen is pleased to confirm that the necessary closing conditions to the Transaction have been met and that
the Transaction will be effective from today, 31 October 2017.

Durban
1 November 2017

Sponsor:
Investec Bank Limited

Date: 01/11/2017 09:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.